Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.

JB Therapeutics is a clinical stage biopharmaceutical company developing the first new class of analgesic agents in two decades. Their lead compound, JBT-101, is a potent CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. It has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is currently being developed as a potential disease modifying treatment for osteoarthritis. JBT-101 also represents a platform for combination with other anti-inflammatory and analgesic agents as well as various drug delivery strategies including ointment and gels, topical patches, and timed release formulations.

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. They have four approved products on the market today and they are not stopping there! From the United States to Europe to the Asia Pacific, they are proud of their multicultural business environment where employees can collaborate with people all over the world. As a group, they are relentless in their pursuit of “medicines for life”® and continue their research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA.

Defensin Therapeutics ApS

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Sunshine Lake Pharma Co. Ltd., a subsidiary of Shenzhen Dongyangguang Industry Co., Ltd., is a Chinese company. The firm manufactures and supplies pharmaceutical ingredients and drugs. Wen Jia Li has been the CEO since 2021. On December 23, 2022 Shenzhen Dongyangguang Industry Co., Ltd. acquired Sunshine Lake Pharma Co. Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. for $330.99 million.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.